BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 35648201)

  • 1. A comparison between patients with various etiologies of cirrhosis and examination of cardiac risk factors limiting survival to liver transplantation.
    Delicce MJ; Mauch J; Sims OT; Lyu R; Kren H; Bartow R; Ferchill D; Joseph A; Fares M; Wakim-Fleming J
    Clin Transplant; 2024 Jan; 38(1):e15210. PubMed ID: 38041421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving trends and outcomes on the US liver transplant waitlist of alcohol-associated hepatitis patients with very high MELD scores.
    Tanaka T; Axelrod D
    Liver Int; 2024 Jun; ():. PubMed ID: 38924203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sepsis Following Liver Biopsy in a Liver Transplant Recipient: Case Report and Review of Literature.
    Agrawal L; Jain S; Madhusudhan KS; Das P; Shalimar ; Dash NR; Sahni P; Pal S
    J Clin Exp Hepatol; 2021; 11(2):254-259. PubMed ID: 33746451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    Kotani K; Enomoto M; Uchida-Kobayashi S; Tamori A; Yukawa-Muto Y; Odagiri N; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Kageyama K; Yamamoto A; Yoshida A; Higashiyama S; Kawabe J; Kawada N
    J Gastroenterol; 2023 Apr; 58(4):394-404. PubMed ID: 36729172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
    Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
    Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
    Matsuoka H; Yamada T; Ohta R; Yoshida Y; Watanabe T; Takahashi M; Kosugi C; Fukazawa A; Kuramochi H; Matsuda A; Sonoda H; Yoshida H; Hasegawa S; Sakamoto K; Otsuka T; Hirata K; Koda K;
    Int J Clin Oncol; 2022 Dec; 27(12):1859-1866. PubMed ID: 36201089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To transplant or not to transplant recurrent hepatitis C and liver failure.
    Forman LM
    Clin Liver Dis; 2003 Aug; 7(3):615-29. PubMed ID: 14509530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allograft liver failure awaiting liver transplantation in Japan.
    Genda T; Ichida T; Tanaka E; Mochida S; Ueno Y; Terai S; Inui A; Ueda Y; Ohdan H; Egawa H; Umeshita K; Furukawa H; Inomata Y
    J Gastroenterol; 2022 Jul; 57(7):495-504. PubMed ID: 35648201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Transplantation: East versus West.
    Shukla A; Vadeyar H; Rela M; Shah S
    J Clin Exp Hepatol; 2013 Sep; 3(3):243-53. PubMed ID: 25755506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.
    Onofrio F; Zheng K; Xu C; Chen S; Xu W; Vyas M; Bingham K; Patel K; Lilly L; Cattral M; Selzner N; Jaeckel E; Tsien C; Gulamhusein A; Hirschfield GM; Bhat M
    Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37534935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system.
    Genda T; Ichida T; Sakisaka S; Sata M; Tanaka E; Inui A; Egawa H; Umeshita K; Furukawa H; Kawasaki S; Inomata Y
    J Gastroenterol; 2014 Feb; 49(2):324-31. PubMed ID: 23478939
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.